Antibe Therapeutics Inc(Pre-Merger) T.ATE

Primary Symbol: ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Weak Hands

<< Previous

Bullboard Posts

Next >>

Comment by WalkOverTheStrton Apr 12, 2021 10:27pm

218 Views

Post# 32982986

RE:RE:RE:Weak Hands

short sighted... lol I'm betting many of us here have held shares for multiple years... and FYI institutions don't hold for years on endless talk without results... firms cull the weak stocks and reallocate often. It is a good thing Antibe is held by retail as funds would have grown impatience on mgmts bleed over timelines and issue questionable raises... . let's get oten in clincial trials database with a start date and execute towards it....and get this holding bs over with

<< Previous

Bullboard Posts

Next >>

Mullen Group: Navigates market challenges towards success